Skip to main content

Advertisement

  • Research article
  • Open Access

Adenosine A2A receptors promote collagen production by a Fli1- and CTGF-mediated mechanism

  • 1Email author,
  • 1,
  • 1, 2,
  • 1,
  • 1,
  • 3,
  • 3 and
  • 1
Arthritis Research & Therapy201315:R58

https://doi.org/10.1186/ar4229

©  Chan et al.; licensee BioMed Central Ltd. 2013

  • Received: 30 July 2012
  • Accepted: 11 May 2013
  • Published:

Abstract

Introduction

Adenosine, acting through the A2A receptor, promotes tissue matrix production in the skin and the liver and induces the development of dermal fibrosis and cirrhosis in murine models. Since expression of A2A receptors is increased in scleroderma fibroblasts, we examined the mechanisms by which the A2A receptor produces its fibrogenic effects.

Methods

The effects of A2A receptor ligation on the expression of the transcription factor, Fli1, a constitutive repressor for the synthesis of matrix proteins, such as collagen, is studied in dermal fibroblasts. Fli1 is also known to repress the transcription of CTGF/CCN2, and the effects of A2A receptor stimulation on CTGF and TGF-β1 expression are also examined.

Results

A2A receptor occupancy suppresses the expression of Fli1 by dermal fibroblasts. A2A receptor activation induces the secretion of CTGF by dermal fibroblasts, and neutralization of CTGF abrogates the A2A receptor-mediated enhancement of collagen type I production. A2AR activation, however, resulted in a decrease in TGF-β1 protein release.

Conclusions

Our results suggest that Fli1 and CTGF are important mediators of the fibrogenic actions of adenosine and the use of small molecules such as adenosine A2A receptor antagonists may be useful in the therapy of dermal fibrosis in diseases such as scleroderma.

Keywords

  • Fibrosis
  • fibroblast
  • scleroderma

Introduction

Matrix production is critical for wound healing and tissue repair but in some clinical settings overproduction of matrix provides the basis for organ injury and dysfunction [1]. In previous studies, we have demonstrated that occupancy of adenosine A2A receptors by an appropriate agonist, such as CGS-21680, promotes more rapid wound closure in both normal mice and diabetic rats and the enhancement in dermal wound healing is accompanied by an increase in matrix (collagen) in the wounds [2–4]. We have recently shown that pharmacological A2AR blockade can be used to diminish scarring while improving the collagen composition and tensile strength of the healed wound [5]. Adenosine A2A receptor agonists such as CGS21680 do not promote wound healing in mice lacking adenosine A2A receptors and these same A2A receptor-deficient mice are protected from the development of hepatic and dermal fibrosis as well [6, 7]. Although exogenous adenosine receptor agonists may promote wound healing, endogenous adenosine production also contributes to wound healing and pathologic fibrosis because mice lacking adenosine A2A receptors have prolonged wound healing and mice that underproduce adenosine in response to appropriate stimuli due to deletion of ecto-5'nucleotidase are protected from the development of hepatic fibrosis [4, 8]. Consistent with the role of matrix overproduction in organ fibrosis and dysfunction, we have further demonstrated that adenosine and its receptor play a critical role in models of hepatic fibrosis/cirrhosis and dermal fibrosis in a model of scleroderma [6, 7, 9] and others have reported that adenosine plays a role in postoperative abdominal adhesions [10].

Although adenosine and adenosine A2A receptors regulate the function of many cell types that stimulate matrix production and fibrosis indirectly, we have reported that stimulation of the A2A receptor on matrix producing fibroblasts in the skin and stellate cells in the liver directly stimulates collagen production [6, 7]. In a murine model deficient for adenosine deaminase, a key catabolizing enzyme for adenosine, we have shown that fibrosis developed spontaneously in the skin in the absence of exogenous fibrogenic stimulators, concomitant with an increase in adenosine levels in the skin [9]. In primary human dermal fibroblasts, the collagen-inducing effect of adenosine can be attributed directly to A2A receptor occupancy, since it is not attenuated by A1 receptor or A2B receptor antagonism, and A3 receptors are not expressed on human dermal fibroblasts [6]. Furthermore, A2A receptor-deficient mice or mice treated with an A2A receptor antagonist are protected against induction of fibrogenesis in the skin by administration of bleomycin [6]. A2A receptor antagonism also diminished dermal fibrogenesis in adenosine deaminase-deficient mice [9]. Lazzerini et al. have shown that expression of adenosine A2A receptors are increased three-fold in dermal fibroblasts isolated from scleroderma patients compared to non-diseased controls, and A2A receptor ligation promotes collagen synthesis in dermal fibroblasts [11]. The adenosine A2A receptor is a GS-linked receptor that stimulates cAMP accumulation and other downstream signals that mediate activation of collagen production by fibroblasts and stellate cells. A number of downstream signals play a role in the stimulation of collagen production by stellate cells including activation of the downstream kinases ERK1/2 (linked to collagen type I production) and p38 MAPKinase (linked to collagen type III production) [12].

Matrix production depends on the balance between forces that promote the transcription of matrix-producing genes and those that repress them. One of the best characterized of such repressors to date is friend leukemia integration-1 (Fli1), a member of the E26 transformation-specific (Ets) transcription factor family [13–16]. Reduction of Fli1 levels in dermal fibroblasts is associated with increased synthesis of connective tissue growth factor (CTGF/CCN2) and type I collagen, as well as a reduction of MMP-1 production [15–19]. This bears much similarity to the well known profibrotic effects of TGF-β. Indeed, enforced expression of Fli1 almost entirely abrogated TGF-β-induced profibrotic gene expression [16], suggesting that Fli1 is a potent endogenous antagonist of TGF-β signaling. Asano and colleagues have recently shown that TGF-β elicits PCAF-dependent acetylation of Fli1, which in turn results in its dissociation from the collagen promoter and subsequent degradation [20, 21]. We therefore hypothesized that one of the possible mechanisms for the fibrogenic effects of adenosine is mediated through suppression of Fli1 expression. Furthermore, since CTGF is a matrix-promoting growth factor regulated by Fli1 and is vastly overexpressed in adenosine deaminase-deficient mice [9, 19], it may also be an important regulator of A2A receptor-mediated fibrous tissue production.

Materials and methods

Reagents

CGS-21680 was purchased from Sigma (St. Louis, MO, USA) and ZM-241385 was from Tocris (Ballwin, MO, USA). Antibody for human Fli1 was from BD Biosciences (San Jose, CA, USA), anti-CTGF and anti β-actin were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), anti-human p84 was from Abcam (Cambridge, MA, USA) and anti-collagen I was purchased from Southern Biotech (Birmingham, AL, USA). Anti-mouse and anti-rabbit immunoglobulins were from DAKO (Carpinteria, CA, USA). DMEM and cell culture reagents were from Invitrogen (Grand Island, NY, USA).

Cell culture

Primary adult human dermal fibroblasts were purchased from Cambrex (East Rutherford, NJ, USA), or Lonza, Inc. (Allendale, NJ, USA). Fibroblasts were cultured in DMEM and used for experiments from first to the fifth passages. For CTGF neutralization, the human dermal fibroblasts where harvested during 16 hours and then incubated with the CTGF antibody (1:250) or normal serum as a control.

Western blotting

To examine expression of Fli1 protein, nuclear extracts from treated dermal fibroblasts were prepared following manufacturer´s instructions (Active Motif Nuclear Extract Protocol, Panomics, Fremont, CA, USA). Protein concentration was measured by BCA method (Pierce, Rockford, IL, USA) using bovine serum albumin as standard. Nuclear extracts (30 µg/lane) were electrophoresed in 12.5% SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). The nitrocellulose membrane was blocked for two hours at room temperature in blocking solution (3% non-fat dry powdered milk in 1x Tween 20 Tris buffered saline (TTBS consisting of 20 mM Tris-HCl, pH 7.4, 150 mM NaCl and 0.1% Tween 20). After blocking, the membrane was incubated with primary antibody Fli1 (1:500; BD Pharmagen, San Jose, CA, USA), p84 (1:1,000; Abcam, Cambridge, MA, USA) or β-Actin (1:1,000; Santa Cruz Biotechnology Inc.,) overnight at 4ºC with gentle shaking on a platform shaker. After incubation with secondary antibody (rabbit anti-mouse immunoglobulins, 1:1,000 dilution, one hour, room temperature), proteins were visualized using the ECF kit (Amersham Biosciences, Little Chalfont, Buckinghamshire, UK). Band intensities were quantified by Adobe Photoshop 7.0.1 software and normalized to p84 nuclear marker level. To examine the expression of CTGF/CCN2, cells were plated 5x104/cm² into six-well plates, starved overnight when cell number reached 75% confluence and supernates were collected following treatment. Samples were concentrated using Microcon Ultracel YM-35 (Millipore, Billerica, MA, USA), and concentrated supernates were electrophoresed in a 10% SDS-polyacrylamide gel. CTGF/CCN2 was detected with primary anti-CTGF/CCN2antibody (1:1,000, Santa Cruz Biotechnology). Collagen type I was assessed in cell lysates as previously described [6].

Reverse transcription and Real-time PCR

Total RNA from treated primary human dermal fibroblasts was isolated using Trizol (Invitrogen, Carlsbad, CA, USA) following stimulation with CGS-21680 (10 µM) according to the manufacturer's protocol. RNA was quantified using spectrophotometric OD260 measurements and quality was assessed by OD260/ OD280 ratio. Reverse transcription was performed using the GeneAmp RNA Core Kit (Applied Biosystems, Carlsbad, CA, USA) in a volume of 25 µl using oligo dT primers and MuLV reverse transcriptase according to the manufacturer's protocol. Real-time PCRs were performed using the SYBR Green PCR Master Mix (Stratagene, Santa Clara, CA, USA) following the manufacturer's instructions and carried out on the Mx3005P™Q-PCR system (Stratagene). Aliquots of reverse transcription reactions were subjected to PCR in 25 µl reactions with SYBR® green using primers for Fli1 [5'- caacacggaagtgctgttgt-3' (forward), 5'-ccaaggggaggacttttgtt-3' (reverse)], CTGF/CCN2 [5'-ttccagagcagctgcaagta-3' (forward), 5'-ctcgtcacacacccactcc-3' (reverse), GAPDH [5'-accatcatccctgcctctac-3' (forward) and 5'-cctgttgctgtagccaaat-3' (reverse)], COL1A1 [5'-tgttcagctttggacctccg-3'(forward), 5'-ccgttctgtacgcaggtgattg-3' (reverse)], and COL3A1 [5'-gaagatgtccttgatgtgc-3'(forward), 5'-agccttgcgtgttcgatat-3'(reverse)].

Primers were designed using output Primer 3 software [22]. The thermal cycling conditions included an initial 95°C for 300 s; then 95°C for 60 s, 58°C for 45 s and 72°C for 45 s for 40 cycles for Fli-1 and 95°C for 300 s; then 95°C for 60 s, 57°C for 45 s and 72°C for 45 s for 40 cycles for CTGF/CCN2. For each assay, standards, no-template and no-RT controls were included to verify the quality and cDNA specificity of the primers. Comparison of the expression of each gene between its control and stimulated states was determined with the delta-delta (ΔΔ)Ct, according to the following formula: (ΔΔ)Ct = ((CtGOI Control - Ct HKG Control) - (CtGOI Stim - Ct HKG Stim)), where GOI (gene of interest) corresponds to Fli1, CTGF or COL1A1 and HKG (housekeeping gene) corresponds to GAPDH. Fold increase was calculated according to the formula: Fold = 2 (ΔΔ)Ct [23].

Determination of transforming growth factor -β1

Normal human dermal fibroblasts were serum starved for 24 h and stimulated with CGS-21680 (1µM). Then, transforming growth factor β1 (TGF-β1) was determined in the supernates after removing the debris by centrifugation with the TGF-β1 ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's protocol.

Statistics

Results are represented as mean ± SEM. Data were analyzed by one-way ANOVA and significance of differences between groups was determined by Newman-Keuls method. Pairwise comparisons were made with the unpaired t-test. All statistical analyses were performed with Graphpad Prism software v. 4.02 (Graphpad Software, La Jolla, CA, USA).

Results

Adenosine A2A receptor activation suppresses Fli1 expression in human dermal fibroblasts

We have previously demonstrated that adenosine A2A receptor activation increases collagen production in dermal fibroblasts, including type I and III collagens [6], although the molecular events involved are unclear. Since suppression of Fli1 expression has also been associated with increased collagen synthesis [16], we investigated whether adenosine A2A receptor activation results in alteration of Fli1 message expression. Following incubation with the adenosine A2A agonist, CGS-21680, Fli1 mRNA expression in dermal fibroblasts was reduced significantly compared to control at four hours (56.8 ± 6.9%, n = 8, P <0.05) (Figure 1A), but not at longer time-points (P = NS). The effect of CGS-21680 on down-regulation of Fli1 message was elicited with CGS-21680 (10 µM), (Figure 1B). While the A2A receptor antagonist ZM241385 did not change the basal values for Fli1 mRNA, the impact of CGS-21680 on Fli1 expression was significantly prevented by coincubation with ZM241385 (1 μM, n = 8, P <0.001 vs CGS) (Figure 1C). Similar to Fli1 message, nuclear Fli1 protein expression in the nucleus was also significantly suppressed by adenosine A2A receptor activation compared to control (71.3 ± 6.3% of control, n = 3, P <0.05), (Figure 2).
Figure 1
Figure 1

Adenosine A 2A receptor occupancy suppresses Fli1 mRNA expression in human dermal fibroblasts. NHDF cells were incubated with CGS-26180 at A) 10 µM at the indicated time-points or B) 1 µM or 10 µM for four or eight hours. C) Incubation with the A2A receptor-selective antagonist ZM241385 (1 µM) prior to CGS-26180 (10 µM) for four hours prevents the decrease on Fli1 expression. Data represent means ± S.E.M. of four to eight independent experiments. *P <0.05 vs. non-stimulated control (One-way ANOVA, post-hoc analysis by Newman-Keuls test); ###P <0.001, CGS-26180 + ZM241385 vs. CGS-26180 (unpaired t-test).

Figure 2
Figure 2

Adenosine A 2A receptor occupancy inhibits nuclear Fli1 protein expression in human dermal fibroblasts. NHDF cells were incubated with CGS-26180 at 1 to 10 µM over 24 hours and cellular fractionation was performed as described under "Methods". A) Representative Western-blot images showing Fli1 and the nuclear marker p84. B) Bands were quantified and data represent means ± S.E.M. from three independent experiments. Statistics were performed by one-way ANOVA with post-hoc analysis by Newman-Keuls test, *P <0.05 vs. non-stimulated control.

Adenosine A2A receptor activation promotes CTGF secretion by dermal fibroblasts

We have previously reported that immunohistochemical staining for CTGF (CCN2) is increased in adenosine deaminase-deficient mice which have high tissue and circulating adenosine levels compared to wild-type littermate control mice [9] and therefore sought to determine whether the effects of adenosine A2A receptor activation on fibroblast function is associated with enhanced CTGF production. Message for CTGF in dermal fibroblasts was increased to 1.47 ± 0.11-fold that of control following treatment with the A2A receptor agonist, CGS-21680 (n = 8, P <0.05 vs. control) (Figure 3A). The CGS-21680-induced increase in CTGF was reversed by pretreatment with the A2A antagonist ZM142385, while ZM241385 alone did not alter CTGF mRNA expression. While Fli1 nuclear protein expression was decreased, CTGF protein levels in supernates (secreted CTGF) and cell-associated CTGF (total lysate) in dermal fibroblast cultures treated with CGS-21680 were also increased (to 160.3 ± 18.7% of control, secreted CTGF, n = 5, P <0.05; and 127.0 ± 6.0% of control, total lysate, P = NS, respectively) (Figure 3B).
Figure 3
Figure 3

Adenosine A 2A receptor occupancy increases CTGF mRNA and protein expression and secretion. NHDF cells were incubated with CGS-26180 at 1 µM A) for 4 hours for CTGF mRNA analysis or B) for 24 hours prior to cellular fractionation and protein concentration from supernates as described under "Methods". Bands were quantified and data represent means ± S.E.M. from three to eight independent experiments. Statistics were performed by one-way ANOVA with post-hoc analysis by Newman-Keuls test, *P <0.05 vs. non-stimulated control.

CTGF is necessary for A2A receptor-mediated collagen type I production

We have previously shown that adenosine A2A receptor occupancy promotes collagen type I production at both the message and protein levels [6]. Since A2A receptor occupancy also enhanced CTGF secretion, we determined whether CTGF is a prerequisite for A2A receptor-mediated collagen I production. We first investigated the mRNA levels for COL1A1 (Figure 4A), and found a significant increase following incubation with CGS-21680 (1.47 ± 0.23-fold of control, n = 6, P <0.05). We therefore sought to analyze the protein levels of collagen I and, as previously demonstrated [6, 12], we found that CGS-21680 treatment increased collagen I protein by 50.1 ± 2.3% compared with control (n = 3, P <0.001) (Figure 4B). However, the addition of a neutralizing antibody to CTGF completely abrogated the CGS-21680-induced increase in collagen I protein (101.7 ± 7.6% of control, n = 3, P <0.001 vs.CGS), but control antiserum did not diminish the CGS21680-induced increase (161.2 ± 3.3% of control, n = 3, P = NS). These results suggest that increased secretion of CTGF is involved in the A2A receptor-mediated collagen I production.
Figure 4
Figure 4

CTGF is involved in the A 2A receptor-mediated collagen production. NHDF cells were incubated with CGS-26180 at 1 µM over A) 4 h for COL1A1 mRNA analysis or B) during 24 h for Western-blotting after 16 h-starvation. Where indicated, the neutralizing antibody to CTGF (Ab; 1:250) or the A2AR antagonist ZM241385 (10 µM) was added prior to incubation with CGS-21680. Bands were quantified and data represent means ± S.E.M. from three to six independent experiments. Statistics were performed by one-way ANOVA with post-hoc analysis by Newman-Keuls test, ***P <0.001 CGS-26180 vs. non-stimulated control; ###P <0.001 CGS-26180 vs. CGS-26180 + CTGF Ab; and NS = non-significant, CGS-26180 vs. CGS-26180 + Normal Serum.

A2AR activation prevents TGF-β1 release

It has been previously described that A2AR stimulation increases the profibrogenic factor TGF-β1 at the mRNA level in T cells [24]. Similarly, A2AR-deficient mice exhibit highly decreased levels of TGF-β [25]. Since it is well- known that TGF-β1 down-regulation of Fli1 promotes fibrogenesis [20, 26–28], to rule out the possibility that the Fli1/ CTGF/ collagen pathway was induced via up-regulation of TGF-β1 following CGS21680 incubation, we studied TGF-β1 release after A2AR activation. As shown in Figure 5, released TGF-β1 was significantly reduced following two-hour incubation with the A2AR agonist, CGS21680. After 24 h, released TGF-β1 levels were restored.
Figure 5
Figure 5

TGF-β1 secretion is decreased by A 2A R activation at earlier time points and restored after 24 hours. NHDF cells were serum-starved and incubated with CGS-26180 1 µM at the indicated time periods and released TGF-β1 levels were analyzed by ELISA. Data represent means ± S.E.M. from four independent experiments. Statistics were performed by unpaired-t test, ***P <0.001, **P <0.01, vs. non-stimulated control.

Discussion

We have previously shown that adenosine promotes fibrogenesis in the skin in vivo [9], that A2AR blockade prevents scarring in vivo [5] and activation of the adenosine A2A receptor but not A1 or A2B receptors promotes dermal extracellular matrix protein production including type I collagen in primary human dermal fibroblasts, and in a murine model of scleroderma [6]. Others have shown that adenosine A2A receptor ligation increases collagen production and induces a pro-fibrotic phenotype in dermal fibroblasts isolated from scleroderma patients, in part by activation of the CB1 cannabinoid receptor [11].The present study strongly suggests, for the first time to our knowledge that an important mechanism for the adenosine-mediated promotion of fibrogenesis occurs at least in part through the regulation of the Ets factor, Fli1, and connective tissue growth factor (CTGF; CCN2). The importance of Fli1 in the regulatory mechanism involved in the transcriptional control of collagen gene expression has been well-described. Characterization of the COL1A2 promoter has identified a critical Ets-binding site mediating Fli1 inhibition [15]. In fact, Fli1 has been previously described to function as a key regulator of the collagen homeostasis in the skin in vivo by repressing the collagen genes COL1A1, COL1A2, COL3A1, COL5A1 and COL5A2 [21] and has also been shown to be significantly reduced in clinically involved skin of patients with scleroderma [16]. Other studies have shown that inhibition of Fli1 by TGF-β and the subsequent displacement of Fli1 from the CTGF promoter results in the up-regulation of CTGF and the COL1A1 and COL1A2 genes in human dermal fibroblasts, strongly suggesting that TGF-β-mediated Fli1 suppression is involved in the activation of the profibrogenic gene program in fibroblasts [19]. In this regard, the secreted protein CTGF [29, 30] is a major mediator of the profibrotic effects of TGF-β [19] and an important mediator of fibrosis since its constitutive expression in fibroblasts is sufficient to promote fibrotic disease in vivo [31].

Transforming growth factor (TGF-β) is known to be a critical regulator of matrix synthesis [26–28], and Fli1 is phosphorylated and acetylated following TGF-β1 treatment in dermal fibroblasts [21, 26–28]. On the other hand, acetylation of Fli1 by TGF-β1 renders the Fli1 protein less stable, providing an important mechanism for the pro-fibrotic actions of TGF-β1 [20, 26–28]. Previous reports suggest a link between dysregulation of Fli1 protein and scleroderma. Fli1 protein is markedly down-regulated in lesional fibroblasts from scleroderma patients [16]. Epigenetic mechanisms may also be responsible, in part, for the repression of Fli1 gene in scleroderma in vivo and increased methylation of the Fli1 promoter region has been demonstrated in SSc fibroblasts and skin biopsies from SSc patients [32]. Our prior work indicates that adenosine and the A2A receptor play a role in fibrosis in models of scleroderma. Mice lacking the A2A receptor are protected from development of dermal fibrosis following bleomycin exposure and A2A receptor activation promotes collagen type I and III production [12]. We, therefore, sought to analyze if the A2A receptor regulates collagen production via Fli1 and CTGF pathways.

Our present studies have shown that adenosine A2A receptor activation in human dermal fibroblasts with the agonist CGS-21680 promotes a reduction of Fli1 mRNA and protein expression in the nucleus, as well as increases in CTGF mRNA and protein expression and secretion. These findings are consistent with previous observations that Fli1 directly inhibits CTGF expression, and knockdown of Fli1 dramatically up-regulates CTGF in dermal fibroblasts [19]. Furthermore A2A receptor activation promotes an increase in collagen type I production which is prevented by CTGF neutralization (Figure 4B). This strongly suggests that Fli1 down-regulation and CTGF up-regulation precede collagen induction upon A2AR activation. Interestingly, release of TGF-β1 was reduced by A2AR activation. Our results therefore raise the possibility that A2AR and TGF-β1 may prevent excessive fibrosis by compensating its redundant pro-fibrogenic effects.

Recently, it has been suggested that hypoxia promotes fibrogenesis [33, 34]. In particular, hypoxia up-regulates CTGF expression through activation of HIF-1α in dermal fibroblasts from scleroderma patients, and thereby contributes to the progression of skin fibrosis [35]. In this respect, as a critical mediator during hypoxia, the actions of adenosine are potentiated by HIF, which has been shown to stimulate the production of extracellular adenosine [36, 37], and suppresses both adenosine uptake into the intracellular compartment and its intracellular metabolism [36, 38, 39] (reviewed in [40]). In fact, although HIF-1α has been shown to up-regulate A2BR during conditions of hypoxia [39] suggesting a role for the A2BR in tissue protection [41][42], the A2AR may likely contribute to the role of adenosine in ischemic settings [39, 42]. Therefore, further studies will be needed to fully understand the interplay between hypoxia, HIF-1α and adenosine in skin fibrosis.

A schema for the involvement of the described pathways in promoting the profibrotic effects of A2A receptor activation is provided in Figure 6. Taken together, these data suggest that the A2A receptor-mediated increase in collagen type I is, at least in part, mediated by Fli1 down-regulation and therefore CTGF and collagen gene derepression. Thus, the adenosine A2A receptor-mediated loss of inhibition of dermal matrix protein synthesis through regulation of Fli1, and the resultant increase in the production of matrix and profibrogenic growth factors such as CTGF, is likely a contributor to the pathogenesis of skin thickening in scleroderma.
Figure 6
Figure 6

Schema depicting the contribution of the Fli1 and CTGF pathways on the A 2A receptor-mediated increase in collagen production.

Conclusions

In summary, the results of our present work confirm previous observations of the role of the adenosine A2A receptor in the pathogenesis of dermal fibrosis in conditions such as scleroderma by promoting the production of tissue matrix and profibrotic mediators. These studies suggest new mechanisms for the profibrogenic effects of the A2A receptor by suppressing Fli1 expression and increasing CTGF secretion. Such mechanisms may play a role in matrix production in other fibrosing diseases, such as cirrhosis, and these mechanistic targets may be further explored as potential anti-fibrotic therapies.

Abbreviations

A2AR: 

Adenosine A2A receptor

Col1: 

collagen type I

Fli1: 

Friend leukemia integration 1 transcription factor

CTGF: 

connective tissue growth factor. HIF: Hypoxia-Inducible Factor.

Declarations

Acknowledgements

This study was funded by grants from the National Institutes of Health AR057544 (EC), AR56672 and AR54897, (BC), AR42334 (MT), the Scleroderma Foundation (EC). In addition this work was supported by the NYU-HHC CTSI (UL1RR029893). The authors thank EUSTAR (EULAR Scleroderma Trials and Research Group), in particular, Dr. Oliver Distler, Dr. Tatiana Nevskaja and Prof. Marco Matucci-Cerinic for their help and participation in these studies.

Authors’ Affiliations

(1)
Department of Medicine, New York University School of Medicine, 550 First Ave., New York, NY 10016, USA
(2)
Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, NIH, Bethesda, MD 20892, USA
(3)
Department of Medicine, Arthritis Center, Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA

References

  1. Denham JW, Hauer-Jensen M: The radiotherapeutic injury--a complex 'wound'. Radiother Oncol. 2002, 63: 129-145. 10.1016/S0167-8140(02)00060-9.View ArticlePubMedGoogle Scholar
  2. Montesinos MC, Desai A, Chen JF, Yee H, Schwarzschild MA, Fink JS, Cronstein BN: Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. Am J Pathol. 2002, 160: 2009-2018. 10.1016/S0002-9440(10)61151-0.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Montesinos MC, Gadangi P, Longaker M, Sung J, Levine J, Nilsen D, Reibman J, Li M, Jiang CK, Hirschhorn R, Recht PA, Ostad E, Levin RI, Cronstein BN: Wound healing is accelerated by agonists of adenosine A2 (G alpha s-linked) receptors. J Exp Med. 1997, 186: 1615-1620. 10.1084/jem.186.9.1615.PubMed CentralView ArticlePubMedGoogle Scholar
  4. Victor-Vega C, Desai A, Montesinos MC, Cronstein BN: Adenosine A2A receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (Becaplermin gel). Inflammation. 2002, 26: 19-24. 10.1023/A:1014417728325.View ArticlePubMedGoogle Scholar
  5. Perez-Aso M, Chiriboga L, Cronstein BN: Pharmacological blockade of adenosine A2A receptors diminishes scarring. FASEB J. 2012, 26: 4254-4263. 10.1096/fj.12-209627.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Chan ES, Fernandez P, Merchant AA, Montesinos MC, Trzaska S, Desai A, Tung CF, Khoa DN, Pillinger MH, Reiss AB, Tomic-Canic M, Chen JF, Schwarzschild MA, Cronstein BN: Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum. 2006, 54: 2632-2642. 10.1002/art.21974.View ArticlePubMedGoogle Scholar
  7. Chan ES, Montesinos MC, Fernandez P, Desai A, Delano DL, Yee H, Reiss AB, Pillinger MH, Chen JF, Schwarzschild MA, Friedman SL, Cronstein BN: Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol. 2006, 148: 1144-1155. 10.1038/sj.bjp.0706812.PubMed CentralView ArticlePubMedGoogle Scholar
  8. Peng Z, Fernandez P, Wilder T, Yee H, Chiriboga L, Chan ES, Cronstein BN: Ecto-5'-nucleotidase (CD73) -mediated extracellular adenosine production plays a critical role in hepatic fibrosis. FASEB J. 2008, 22: 2263-2272. 10.1096/fj.07-100685.View ArticlePubMedGoogle Scholar
  9. Fernandez P, Trzaska S, Wilder T, Chiriboga L, Blackburn MR, Cronstein BN, Chan ES: Pharmacological blockade of A2A receptors prevents dermal fibrosis in a model of elevated tissue adenosine. Am J Pathol. 2008, 172: 1675-1682. 10.2353/ajpath.2008.070952.PubMed CentralView ArticlePubMedGoogle Scholar
  10. Jackson EK: Intraperitoneal administration of adenosine inhibits formation of abdominal adhesions. Dis Colon Rectum. 2004, 47: 1390-1396. 10.1007/s10350-004-0578-z.View ArticlePubMedGoogle Scholar
  11. Lazzerini PE, Natale M, Gianchecchi E, Capecchi PL, Montilli C, Zimbone S, Castrichini M, Balistreri E, Ricci G, Selvi E, Garcia-Gonzalez E, Galeazzi M, Laghi-Pasini F: Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system. J Mol Med (Berl). 2012, 90: 331-342. 10.1007/s00109-011-0824-5.View ArticleGoogle Scholar
  12. Che J, Chan ES, Cronstein BN: Adenosine A2A receptor occupancy stimulates collagen expression by hepatic stellate cells via pathways involving protein kinase A, Src, and extracellular signal-regulated kinases 1/2 signaling cascade or p38 mitogen-activated protein kinase signaling pathway. Mol Pharmacol. 2007, 72: 1626-1636. 10.1124/mol.107.038760.View ArticlePubMedGoogle Scholar
  13. Asano Y, Bujor AM, Trojanowska M: The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis. J Dermatol Sci. 2010, 59: 153-162. 10.1016/j.jdermsci.2010.06.008.View ArticlePubMedGoogle Scholar
  14. Asano Y, Markiewicz M, Kubo M, Szalai G, Watson DK, Trojanowska M: Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. Mol Cell Biol. 2009, 29: 425-434. 10.1128/MCB.01278-08.PubMed CentralView ArticlePubMedGoogle Scholar
  15. Czuwara-Ladykowska J, Shirasaki F, Jackers P, Watson DK, Trojanowska M: Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem. 2001, 276: 20839-20848. 10.1074/jbc.M010133200.View ArticlePubMedGoogle Scholar
  16. Kubo M, Czuwara-Ladykowska J, Moussa O, Markiewicz M, Smith E, Silver RM, Jablonska S, Blaszczyk M, Watson DK, Trojanowska M: Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol. 2003, 163: 571-581. 10.1016/S0002-9440(10)63685-1.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Jinnin M, Ihn H, Mimura Y, Asano Y, Yamane K, Tamaki K: Matrix metalloproteinase-1 up-regulation by hepatocyte growth factor in human dermal fibroblasts via ERK signaling pathway involves Ets1 and Fli1. Nucleic Acids Res. 2005, 33: 3540-3549. 10.1093/nar/gki648.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Jinnin M, Ihn H, Yamane K, Mimura Y, Asano Y, Tamaki K: Alpha2(I) collagen gene regulation by protein kinase C signaling in human dermal fibroblasts. Nucleic Acids Res. 2005, 33: 1337-1351. 10.1093/nar/gki275.PubMed CentralView ArticlePubMedGoogle Scholar
  19. Nakerakanti SS, Kapanadze B, Yamasaki M, Markiewicz M, Trojanowska M: Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem. 2006, 281: 25259-25269. 10.1074/jbc.M600466200.View ArticlePubMedGoogle Scholar
  20. Asano Y, Czuwara J, Trojanowska M: Transforming growth factor-beta regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem. 2007, 282: 34672-34683. 10.1074/jbc.M703907200.View ArticlePubMedGoogle Scholar
  21. Asano Y, Trojanowska M: Phosphorylation of Fli1 at threonine 312 by protein kinase C delta promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor beta. Mol Cell Biol. 2009, 29: 1882-1894. 10.1128/MCB.01320-08.PubMed CentralView ArticlePubMedGoogle Scholar
  22. Rozen S, Skaletsky H: Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000, 132: 365-386.PubMedGoogle Scholar
  23. Dussault AA, Pouliot M: Rapid and simple comparison of messenger RNA levels using real-time PCR. Biol Proced Online. 2006, 8: 1-10. 10.1251/bpo114.PubMed CentralView ArticlePubMedGoogle Scholar
  24. Zarek PE, Huang CT, Lutz ER, Kowalski J, Horton MR, Linden J, Drake CG, Powell JD: A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood. 2008, 111: 251-259. 10.1182/blood-2007-03-081646.PubMed CentralView ArticlePubMedGoogle Scholar
  25. Nowak M, Lynch L, Yue S, Ohta A, Sitkovsky M, Balk SP, Exley MA: The A2aR adenosine receptor controls cytokine production in iNKT cells. Eur J Immunol. 2010, 40: 682-687. 10.1002/eji.200939897.PubMed CentralView ArticlePubMedGoogle Scholar
  26. Trojanowska M, Varga J: Molecular pathways as novel therapeutic targets in systemic sclerosis. Curr Opin Rheumatol. 2007, 19: 568-573. 10.1097/BOR.0b013e3282e6f495.View ArticlePubMedGoogle Scholar
  27. Varga JA, Trojanowska M: Fibrosis in systemic sclerosis. Rheum Dis Clin North Am. 2008, 34: 115-143. 10.1016/j.rdc.2007.11.002. viiView ArticlePubMedGoogle Scholar
  28. Wynn TA: Cellular and molecular mechanisms of fibrosis. J Pathol. 2008, 214: 199-210. 10.1002/path.2277.PubMed CentralView ArticlePubMedGoogle Scholar
  29. Bradham DM, Igarashi A, Potter RL, Grotendorst GR: Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol. 1991, 114: 1285-1294. 10.1083/jcb.114.6.1285.View ArticlePubMedGoogle Scholar
  30. Gressner OA, Lahme B, Siluschek M, Rehbein K, Weiskirchen R, Gressner AM: Connective tissue growth factor is a Smad2 regulated amplifier of transforming growth factor beta actions in hepatocytes--but without modulating bone morphogenetic protein 7 signaling. Hepatology. 2009, 49: 2021-2030. 10.1002/hep.22850.View ArticlePubMedGoogle Scholar
  31. Sonnylal S, Shi-Wen X, Leoni P, Naff K, Van Pelt CS, Nakamura H, Leask A, Abraham D, Bou-Gharios G, de Crombrugghe B: Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. Arthritis Rheum. 2010, 62: 1523-1532. 10.1002/art.27382.View ArticlePubMedGoogle Scholar
  32. Wang Y, Fan PS, Kahaleh B: Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 2006, 54: 2271-2279. 10.1002/art.21948.View ArticlePubMedGoogle Scholar
  33. Higgins DF, Kimura K, Iwano M, Haase VH: Hypoxia-inducible factor signaling in the development of tissue fibrosis. Cell Cycle. 2008, 7: 1128-1132. 10.4161/cc.7.9.5804.PubMed CentralView ArticlePubMedGoogle Scholar
  34. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, Saito Y, Johnson RS, Kretzler M, Cohen CD, Eckardt KU, Iwano M, Haase VH: Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest. 2007, 117: 3810-3820.PubMed CentralPubMedGoogle Scholar
  35. Hong KH, Yoo SA, Kang SS, Choi JJ, Kim WU, Cho CS: Hypoxia induces expression of connective tissue growth factor in scleroderma skin fibroblasts. Clin Exp Immunol. 2006, 146: 362-370. 10.1111/j.1365-2249.2006.03199.x.PubMed CentralView ArticlePubMedGoogle Scholar
  36. Eckle T, Kohler D, Lehmann R, El Kasmi K, Eltzschig HK: Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation. 2008, 118: 166-175. 10.1161/CIRCULATIONAHA.107.758516.View ArticlePubMedGoogle Scholar
  37. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, Hansen KR, Thompson LF, Colgan SP: Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest. 2002, 110: 993-1002.PubMed CentralView ArticlePubMedGoogle Scholar
  38. Eckle T, Krahn T, Grenz A, Kohler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, Eltzchiq HK: Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation. 2007, 115: 1581-1590. 10.1161/CIRCULATIONAHA.106.669697.View ArticlePubMedGoogle Scholar
  39. Kong T, Westerman KA, Faigle M, Eltzschig HK, Colgan SP: HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB J. 2006, 20: 2242-2250. 10.1096/fj.06-6419com.View ArticlePubMedGoogle Scholar
  40. Eltzschig HK, Carmeliet P: Hypoxia and inflammation. N Engl J Med. 2011, 364: 656-665. 10.1056/NEJMra0910283.PubMed CentralView ArticlePubMedGoogle Scholar
  41. Koeppen M, Eckle T, Eltzschig HK: Interplay of hypoxia and A2B adenosine receptors in tissue protection. Adv Pharmacol. 2011, 61: 145-186.View ArticlePubMedGoogle Scholar
  42. Grenz A, Bauerle JD, Dalton JH, Ridyard D, Badulak A, Tak E, McNamee EN, Clambey E, Moldovan R, Reyes G, Klawitter J, Ambler K, Magee K, Christians U, Brodsky KS, Ravid K, Choi DS, Wen J, Lukashev D, Blackburn MR, Osswald H, Coe IR, Nürnberg B, Haase VH, Xia Y, Sitkovsky M, Eltzschig HK: Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. J Clin Invest. 2012, 122: 693-710. 10.1172/JCI60214.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Chan et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us